Literature DB >> 9684804

Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members.

F Demarmels Biasiutti1, I Sulzer, B Stucki, W A Wuillemin, M Furlan, B Lämmle.   

Abstract

The role of plasminogen (plg) deficiency in the pathogenesis of venous thromboembolism is debated in the literature. In the present study we evaluated the prevalence of plg deficiency in our thrombophilia patients and aimed to elucidate the thrombosis risk of plg deficiency as a single defect or in combination with other defects, with special focus on APC resistance. The study cohort included 1192 consecutive patients with a history of clinically or objectively diagnosed venous and/or arterial thromboembolism and/or positive family history who were referred to our department for thrombophilia investigation from 02/1988 to 03/1997. All available family members of patients with plg deficiency were tested for plg, APC resistance and other thrombophilic defects that were established in the propositus. 23/1192 propositi were plg-deficient corresponding to an overall prevalence of 1.9%, i.e. 2.2% in patients with venous thrombosis and 1.4% in those with arterial events. Out of the 23 plg-deficient propositi, 8 showed one or multiple additional thrombophilic defects, and in 4 patients relevant circumstantial risk factors were present. Of the 53 available family members, 28 were plg-deficient including 5 with additional APC resistance, and 4 subjects had isolated APC resistance. Ten of the 53 family members had already suffered thromboembolic events, i.e. 5 (18%) in the plg-deficient group and 5 (20%) in the non-deficient group, both groups showing an almost identical median age at the time of investigation (28.9 years and 27.1 years, respectively). Based on our data, plg deficiency is a rare defect in thrombophilic patients and as a single defect it does not seem to be a strong thrombotic risk factor, as 11 of 23 propositi had additional thrombophilic defects or circumstantial risk factors, and in the family members thrombotic events were equally frequent in the plg-deficient and non-deficient subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684804

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation.

Authors:  Toshiyuki Miyata; Rina Kimura; Yoshihiro Kokubo; Toshiyuki Sakata
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 2.  Criteria for specific measurement of plasminogen (enzymatic; procedure) in human plasma.

Authors:  Johannes J Sidelmann; Nuala A Booth; Johannes Hoffmann; Michael E Nesheim; Steffen Rosén
Journal:  EJIFCC       Date:  2000-09-01

3.  Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.

Authors:  Verónica Pons; Pável Olivera; Roberto García-Consuegra; Laura López-Andreoni; Nieves Martín-Begué; Angel García; Juliana Hidalgo; Francesc Bosch; Amparo Santamaría
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

Review 4.  Plasminogen deficiency.

Authors:  Tiraje Celkan
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

5.  Hereditary thrombophilia.

Authors:  Salwa Khan; Joseph D Dickerman
Journal:  Thromb J       Date:  2006-09-12

6.  The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease.

Authors:  Laura Martin-Fernandez; Pascual Marco; Irene Corrales; Raquel Pérez; Lorena Ramírez; Sonia López; Francisco Vidal; José Manuel Soria
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

7.  Rare coding variants pinpoint genes that control human hematological traits.

Authors:  Abdou Mousas; Georgios Ntritsos; Ming-Huei Chen; Ci Song; Jennifer E Huffman; Ioanna Tzoulaki; Paul Elliott; Bruce M Psaty; Paul L Auer; Andrew D Johnson; Evangelos Evangelou; Guillaume Lettre; Alexander P Reiner
Journal:  PLoS Genet       Date:  2017-08-07       Impact factor: 5.917

8.  Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.

Authors:  Joline L Saes; Saskia E M Schols; Kathleen F Betbadal; Mark van Geffen; Kitty Verbeek-Knobbe; Sweta Gupta; Brandon M Hardesty; Amy D Shapiro; Waander L van Heerde
Journal:  Haemophilia       Date:  2019-08-30       Impact factor: 4.287

Review 9.  Severe dysplasminogenemia due to homozygous PLG Ala620Thr variant in a Korean woman without a history of venous thromboembolism: A case report and literature review.

Authors:  Beomki Lee; Suekyeung Kim; Jae Joon Lee; Seon-Hee Heo; Suryeun Chung; Shin Yi Jang; Sun-Hee Kim; Duk-Kyung Kim; Hee-Jin Kim
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

10.  Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19.

Authors:  Joe M McCord; Brooks M Hybertson; Adela Cota-Gomez; Kara P Geraci; Bifeng Gao
Journal:  Antioxidants (Basel)       Date:  2020-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.